[go: up one dir, main page]

ECSP20018586A - Compuestos que contienen pirazolopirimidinona y sus usos - Google Patents

Compuestos que contienen pirazolopirimidinona y sus usos

Info

Publication number
ECSP20018586A
ECSP20018586A ECSENADI202018586A ECDI202018586A ECSP20018586A EC SP20018586 A ECSP20018586 A EC SP20018586A EC SENADI202018586 A ECSENADI202018586 A EC SENADI202018586A EC DI202018586 A ECDI202018586 A EC DI202018586A EC SP20018586 A ECSP20018586 A EC SP20018586A
Authority
EC
Ecuador
Prior art keywords
compounds
compounds containing
relates
present
pyrazolopyrimidinone
Prior art date
Application number
ECSENADI202018586A
Other languages
English (en)
Inventor
Leonard Sung
Laura Gillard
Taras Rybak
Mariam Zaky
Hossein Ismaili
George Edwin Katibah
Stephane Ciblat
Tucker Curran Roberts
Vu Linh Ly
Franck Raeppel
Chudi Obioma Ndubaku
Yeeman K Ramtohul
Original Assignee
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech Inc filed Critical Aduro Biotech Inc
Publication of ECSP20018586A publication Critical patent/ECSP20018586A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de pirazolopirimidinona. La presente invención también se refiere a composiciones farmacéuticas que contienen estos compuestos y a métodos para tratar enfermedades autoinmunitarias, inflamatorias y neurodegenerativas mediante la administración de estos compuestos y composiciones farmacéuticas a sujetos que los necesitan. La presente invención también se refiere al uso de tales compuestos para investigación u otros fines no terapéuticos.
ECSENADI202018586A 2017-09-15 2020-03-13 Compuestos que contienen pirazolopirimidinona y sus usos ECSP20018586A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762559482P 2017-09-15 2017-09-15
US201862633248P 2018-02-21 2018-02-21
US201862687769P 2018-06-20 2018-06-20

Publications (1)

Publication Number Publication Date
ECSP20018586A true ECSP20018586A (es) 2020-06-30

Family

ID=65723108

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202018586A ECSP20018586A (es) 2017-09-15 2020-03-13 Compuestos que contienen pirazolopirimidinona y sus usos

Country Status (22)

Country Link
US (1) US10738056B2 (es)
EP (1) EP3681888A4 (es)
JP (1) JP2020533376A (es)
KR (1) KR20200032751A (es)
CN (1) CN111212839A (es)
AU (1) AU2018331456B2 (es)
BR (1) BR112020003676A2 (es)
CA (1) CA3075751A1 (es)
CL (1) CL2020000544A1 (es)
CO (1) CO2020002107A2 (es)
CR (1) CR20200114A (es)
DO (1) DOP2020000051A (es)
EC (1) ECSP20018586A (es)
IL (1) IL273236A (es)
JO (1) JOP20200055A1 (es)
MA (1) MA50256A (es)
MX (1) MX2020002869A (es)
PE (1) PE20210340A1 (es)
PH (1) PH12020500500A1 (es)
SG (1) SG11202002218VA (es)
TW (1) TW201920185A (es)
WO (1) WO2019055750A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3034705C (en) 2016-08-31 2021-08-03 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
SG11202004113VA (en) 2017-11-10 2020-06-29 Takeda Pharmaceuticals Co Sting modulator compounds, and methods of making and using
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
JP7414965B2 (ja) * 2019-08-21 2024-01-16 ザ スクリプス リサーチ インスティテュート インターフェロン遺伝子の刺激因子ｓｔｉｎｇの二環式アゴニスト
CN110724143B (zh) * 2019-10-09 2021-03-23 清华大学 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫系统疾病与肿瘤中的应用
CN110627725B (zh) * 2019-10-14 2022-10-18 遵义医科大学 一种4-取代5-二氟甲基-3-硝基-1h-吡唑类化合物及其制备方法与应用
JOP20220125A1 (ar) 2019-11-25 2023-01-30 Amgen Inc مركبات حلقية غير متجانسة على هيئة مثبطات دلتا-5 ديساتوراز وطرق لاستخدامها
CN113248491B (zh) * 2020-02-11 2022-02-25 中国科学院上海药物研究所 一类取代的吲哚脲衍生物、合成方法及其用途
JP2023525909A (ja) * 2020-05-20 2023-06-19 エフ． ホフマン－ラ ロシュ アーゲー 新規マロニトリル誘導体
JP2023527698A (ja) * 2020-05-20 2023-06-30 エフ． ホフマン－ラ ロシュ アーゲー 新規マロニトリル誘導体
US12509467B2 (en) 2020-05-20 2025-12-30 Hoffmann-La Roche Inc. CGAS inhibiting triazolopyrimidone derivatives
MX2023004369A (es) * 2020-10-14 2023-07-06 C4 Therapeutics Inc Compuestos triciclicos para degradar neosustratos para terapia medica.
US20220168330A1 (en) 2020-11-09 2022-06-02 Takeda Pharmaceutical Company Limited Antibody drug conjugates
CN114644633B (zh) * 2020-12-18 2026-02-03 北京诺诚健华医药科技有限公司 杂环类jak抑制剂
IL303913A (en) 2020-12-22 2023-08-01 Novartis Ag Indole derivatives are useful in the treatment of conditions associated with CGAS
EP4267571A1 (en) * 2020-12-22 2023-11-01 Novartis AG Pyrrolo[3,2-b]pyridine derivatives useful in treating conditions associated with cgas
US20240252598A1 (en) * 2021-04-13 2024-08-01 University Of Washington Designed constitutively active cyclic gmp-amp synthase as a genetically encoded stimulant of interferons
JP2026501225A (ja) * 2022-12-20 2026-01-14 ベンタス・セラピューティクス・ユー・エス・インコーポレイテッド 環状ｇｍｐ－ａｍｐ合成酵素の阻害剤としてのチアジアゾール誘導体及びその使用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS625362A (ja) 1985-06-30 1987-01-12 菊地　真 ハイパ−サ−ミア用加温装置
JPH02131235A (ja) 1988-11-12 1990-05-21 Fuji Photo Film Co Ltd 新規なカプラーを含有するハロゲン化銀写真感光材料
AU639615B2 (en) 1990-10-09 1993-07-29 Otsuka Pharmaceutical Co., Ltd. Pyrimidine derivative, production thereof, and androgen inhibitor
ATE174917T1 (de) * 1991-04-22 1999-01-15 Otsuka Pharma Co Ltd Pyrazolo(1,5-a>pyrimidinderivate und sie enthaltende antiinflammatorische mittel
CN1169149A (zh) 1995-09-28 1997-12-31 株式会社大制药工场 止痛组合物
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
FR2746309B1 (fr) 1996-03-22 1998-04-17 Oreal Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
KR100382964B1 (ko) * 1997-03-14 2003-05-09 오쓰까 세이야꾸 가부시키가이샤 신규 피리미딘 유도체
JP3625362B2 (ja) 1997-09-08 2005-03-02 コニカミノルタホールディングス株式会社 感熱転写記録材料及び感熱転写記録方法
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
JP4933730B2 (ja) 2001-05-04 2012-05-16 パラテック ファーマシューティカルズ インコーポレイテッド 転写因子調節化合物およびその使用法
US7405235B2 (en) 2001-05-04 2008-07-29 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
ATE389656T1 (de) 2002-06-04 2008-04-15 Neogenesis Pharmaceuticals Inc Pyrazolo(1,5-a)pyrimidin-verbindungen als antivirale agentien
US7449488B2 (en) 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
AU2003291226B2 (en) 2002-11-01 2009-06-04 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
JP2005008581A (ja) * 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
AU2005324492B2 (en) 2004-04-23 2012-06-07 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
PT2188291E (pt) 2007-08-14 2012-12-20 Bayer Ip Gmbh Pirimidinas bicíclicas fundidas
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009071705A1 (en) * 2007-12-07 2009-06-11 Galapagos Nv Pyrazolepyrimidine compounds useful for the treatment of degenerative & inflammatory diseases
CA2708300A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
ES2422741T3 (es) * 2007-12-13 2013-09-13 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CN101906105B (zh) 2009-06-08 2013-01-16 河北医科大学 吡唑并[1，5-a]嘧啶酮衍生物及其药物组合物以及其用途
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
DK2603511T3 (en) * 2010-08-12 2017-05-08 Boehringer Ingelheim Int 6-CYCLOALKYL-1, 5-DIHYDRO-PYRAZOLO- [3,4-D] PYRIMIDIN-4-ON DERIVATIVES AND THEIR USES AS PDE9A INHIBITORS
AU2011310713A1 (en) 2010-09-27 2013-04-11 Proximagen Ltd 7-hydroxy-pyrazolo[1,5-a] pyrimidine compounds and their use as CCR2 receptor antagonists
US10953012B2 (en) * 2011-04-26 2021-03-23 Bioenergenix Llc Heterocyclic compounds for the inhibition of pask
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
RU2014146778A (ru) 2012-05-23 2016-07-10 Савира Фармасьютикалз Гмбх Производные 7-оксо-4,7-дигидропиразоло[1,5-а]пиримидина, которые пригодны для лечения, уменьшения интенсивности или предупреждения вирусного заболевания
US9434745B2 (en) 2012-05-23 2016-09-06 Savira Pharmaceuticals Gmbh 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
MX2015001478A (es) 2012-08-06 2015-08-12 Savira Pharmaceuticals Gmbh Derivados de acido dihidroxipirimidina, carbonico y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
BR112015022545A2 (pt) 2013-03-13 2017-07-18 Constellation Pharmaceuticals Inc compostos de pirazolo e os usos disso
CA2922925A1 (en) 2013-09-05 2015-03-12 Genentech, Inc. Antiproliferative compounds
WO2015135094A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic compounds and uses thereof
WO2015183989A1 (en) 2014-05-27 2015-12-03 Navigen, Inc. Arf6 inhibitors and methods of synthesis and use thereof
CN106146508A (zh) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途
US10787462B2 (en) 2015-10-23 2020-09-29 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3394032A4 (en) 2015-12-21 2019-09-18 The University of Chicago COMPOUNDS AND METHODS OF TREATMENT, DETECTION AND IDENTIFICATION OF COMPOUNDS FOR THE TREATMENT OF PARASITIC ILLNESSES BY APICOMPLEXA
JP7051703B2 (ja) 2016-04-15 2022-04-11 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ピラゾロピリミジン誘導体
WO2017210678A1 (en) 2016-06-03 2017-12-07 An2H Discovery Limited Pyrazolopyrimidine derivatives and the compositions and methods of treatment regarding the same
CA3034705C (en) 2016-08-31 2021-08-03 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
WO2018039972A1 (en) 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
WO2018229683A1 (en) 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
WO2019040499A2 (en) * 2017-08-21 2019-02-28 Navigen, Inc. ARF6 INHIBITORS AND ASSOCIATED METHODS

Also Published As

Publication number Publication date
CN111212839A (zh) 2020-05-29
CA3075751A1 (en) 2019-03-21
KR20200032751A (ko) 2020-03-26
EP3681888A1 (en) 2020-07-22
WO2019055750A1 (en) 2019-03-21
EP3681888A4 (en) 2021-07-07
CO2020002107A2 (es) 2020-05-29
AU2018331456B2 (en) 2020-10-08
JOP20200055A1 (ar) 2020-03-10
JP2020533376A (ja) 2020-11-19
MX2020002869A (es) 2020-07-24
TW201920185A (zh) 2019-06-01
CR20200114A (es) 2020-06-01
MA50256A (fr) 2020-07-22
US20190119285A1 (en) 2019-04-25
PE20210340A1 (es) 2021-02-22
SG11202002218VA (en) 2020-04-29
CL2020000544A1 (es) 2020-10-02
BR112020003676A2 (pt) 2020-09-01
US10738056B2 (en) 2020-08-11
AU2018331456A1 (en) 2020-03-05
IL273236A (en) 2020-04-30
DOP2020000051A (es) 2020-08-15
PH12020500500A1 (en) 2021-03-01

Similar Documents

Publication Publication Date Title
ECSP20018586A (es) Compuestos que contienen pirazolopirimidinona y sus usos
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
SV2016005311A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CL2016001579A1 (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos.
SV2018005771A (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
MX391171B (es) Anticuerpos anti-cd19 humano con alta afinidad
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
CL2017002106A1 (es) Anticuerpos contra tau y sus usos
DOP2017000298A (es) Reguladores de nrf2
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2015012456A (es) Compuestos heterociclicos y usos de los mismos.
BR112018012262A2 (pt) composições de interleucina-15 e seus usos
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
CL2017000372A1 (es) Composiciones novedosas, usos y métodos para hacerlas.
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
MX384363B (es) Nuevos polipéptidos de unión específica y usos de los mismos.
CO2018005315A2 (es) Moduladores de la interacción de sestrina-gator2 y sus usos
MX2019012428A (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
CO2018002211A2 (es) Piridinona dicarboxamida para su uso como inhibidores de bromodominio
MX2018001756A (es) Benzimidazoles sustituidos, su preparacion y su uso como productos farmaceuticos.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t